SciELO - Scientific Electronic Library Online

 
vol.22 issue1Impact of Chronic Endometritis on Female FertilityNeuroEPO influence on the fetal heart in a placental insufficiency model of rats author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


MediSur

On-line version ISSN 1727-897X

Abstract

LAURENCIO VALLINA, Sandra Caridad et al. Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021. Medisur [online]. 2024, vol.22, n.1, pp. 120-126.  Epub Feb 28, 2024. ISSN 1727-897X.

ABSTRACT

Foundation

SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country.

Objective

to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients.

Methods

a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records.

Results

morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%).

Conclusions

resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases.

Keywords : Coronavirus infections; immunologic factors; morbidity; mortality; treatment outcome.

        · abstract in Spanish     · text in Spanish